BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precis Oncol 2017;2017. [PMID: 29951597 DOI: 10.1200/PO.17.00146] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Yu L, Gong C. Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes. Front Genet 2022;13:917118. [DOI: 10.3389/fgene.2022.917118] [Reference Citation Analysis]
2 Wozniakova M, Skarda J, Raska M. The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. Pathol Oncol Res 2022;28:1610502. [DOI: 10.3389/pore.2022.1610502] [Reference Citation Analysis]
3 Walker R, Georgeson P, Mahmood K, Joo JE, Makalic E, Clendenning M, Como J, Preston S, Joseland S, Pope BJ, Hutchinson R, Kasem K, Walsh MD, Macrae FA, Win AK, Hopper JL, Mouradov D, Gibbs P, Sieber OM, O’sullivan DE, Brenner DR, Gallinger S, Jenkins MA, Rosty C, Winship IM, Buchanan DD. Evaluating multiple next-generation sequencing derived tumor features to accurately predict DNA mismatch repair status.. [DOI: 10.1101/2022.06.20.22276419] [Reference Citation Analysis]
4 Panda A, Betigeri A, Ganesan S. A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade. Front Genet 2022;13:706468. [DOI: 10.3389/fgene.2022.706468] [Reference Citation Analysis]
5 Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 2021;17:3837-49. [PMID: 34671202 DOI: 10.7150/ijbs.64077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
6 Liotta LA, Pappalardo PA, Carpino A, Haymond A, Howard M, Espina V, Wulfkuhle J, Petricoin E. Laser Capture Proteomics: Spatial Tissue Molecular Profiling from the bench to personalized medicine. Expert Rev Proteomics 2021. [PMID: 34607525 DOI: 10.1080/14789450.2021.1984886] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tong K, Kothari OA, Haro KS, Panda A, Bandari MM, Carrick JN, Hur JJ, Zhang L, Chan CS, Xing J, Gatza ML, Ganesan S, Verzi MP. SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. Oncogene 2021;40:6034-48. [PMID: 34453124 DOI: 10.1038/s41388-021-01997-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Panda A, Ganesan S. Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer. Front Genet 2021;12:706435. [PMID: 34367262 DOI: 10.3389/fgene.2021.706435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol 2021;13:1758835921992992. [PMID: 33717226 DOI: 10.1177/1758835921992992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
11 Huang J, Liu H, Zhao Y, Luo T, Liu J, Liu J, Pan X, Tang W. MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer. Front Oncol 2020;10:550986. [PMID: 33634010 DOI: 10.3389/fonc.2020.550986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ng S, Lim S, Sim ACN, Mangadu R, Lau A, Zhang C, Martinez SB, Chandramohan A, Lim U, Ho SSW, Chang SC, Gopal P, Hong LZ, Schwaid A, Fernandis AZ, Loboda A, Li C, Phan U, Henry B, Partridge AW. STUB1 is an intracellular checkpoint for interferon gamma sensing.. [DOI: 10.1101/2020.12.14.420539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci 2020;21:E8984. [PMID: 33256089 DOI: 10.3390/ijms21238984] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 18.0] [Reference Citation Analysis]
14 Poillet-Perez L, Sharp DW, Yang Y, Laddha SV, Ibrahim M, Bommareddy PK, Sherrie Hu Z, Vieth J, Haas M, Bosenberg MW, Rabinowitz JD, Cao J, Guan JL, Ganesan S, Chan CS, Mehnert JM, Lattime EC, White E. Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nat Cancer 2020;1:923-34. [PMID: 34476408 DOI: 10.1038/s43018-020-00110-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
15 Brueffer C, Gladchuk S, Winter C, Vallon-Christersson J, Hegardt C, Häkkinen J, George AM, Chen Y, Ehinger A, Larsson C, Loman N, Malmberg M, Rydén L, Borg Å, Saal LH. The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome. EMBO Mol Med 2020;12:e12118. [PMID: 32926574 DOI: 10.15252/emmm.202012118] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
16 O'Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K, Pelekanou V, Rimm DL, Pusztai L. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers. JCO Precis Oncol 2020;4:PO. [PMID: 32923897 DOI: 10.1200/PO.19.00350] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
17 Panda A, Rosenfeld JA, Singer EA, Bhanot G, Ganesan S. Genomic and immunologic correlates of LAG-3 expression in cancer. Oncoimmunology 2020;9:1756116. [PMID: 32923111 DOI: 10.1080/2162402X.2020.1756116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
18 Alicea GM, Rebecca VW. Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell Melanoma Res 2021;34:44-58. [PMID: 32274887 DOI: 10.1111/pcmr.12880] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
19 Damilakis E, Mavroudis D, Sfakianaki M, Souglakos J. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival? Cancers (Basel) 2020;12:E889. [PMID: 32268531 DOI: 10.3390/cancers12040889] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
20 Brueffer C, Gladchuk S, Winter C, Vallon-christersson J, Hegardt C, Häkkinen J, George AM, Chen Y, Ehinger A, Larsson C, Loman N, Malmberg M, Rydén L, Borg Å, Saal LH. The Mutational Landscape of the SCAN-B Real-World Primary Breast Cancer Transcriptome.. [DOI: 10.1101/2020.01.30.926733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1798. [PMID: 31731749 DOI: 10.3390/cancers11111798] [Cited by in Crossref: 59] [Cited by in F6Publishing: 68] [Article Influence: 19.7] [Reference Citation Analysis]
22 Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immunother Cancer 2019;7:307. [PMID: 31730025 DOI: 10.1186/s40425-019-0796-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
23 Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer 2019;7:183. [PMID: 31307554 DOI: 10.1186/s40425-019-0647-4] [Cited by in Crossref: 148] [Cited by in F6Publishing: 160] [Article Influence: 49.3] [Reference Citation Analysis]
24 Roos A, Byron SA. Genomics-Enabled Precision Medicine for Cancer. Cancer Treat Res 2019;178:137-69. [PMID: 31209844 DOI: 10.1007/978-3-030-16391-4_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
25 Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018;362:eaar3593. [PMID: 30309915 DOI: 10.1126/science.aar3593] [Cited by in Crossref: 1035] [Cited by in F6Publishing: 1063] [Article Influence: 258.8] [Reference Citation Analysis]
26 Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG, Serody JS, Beckermann KE, Ganesan S, Bhanot G, Rathmell WK. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 2018;3:121522. [PMID: 30135306 DOI: 10.1172/jci.insight.121522] [Cited by in Crossref: 96] [Cited by in F6Publishing: 98] [Article Influence: 24.0] [Reference Citation Analysis]
27 Tolba KA, Knight Cancer Institute, Oregon Health & Science University, Division of Hematology and Medical Oncology, Portland, OR, US. Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer. Oncology & Hematology Review (US) 2018;14:67. [DOI: 10.17925/ohr.2018.14.2.67] [Reference Citation Analysis]